Milestones in tumor vascularization and its therapeutic targeting.

Research into the mechanisms and manifestations of solid tumor vascularization was launched more than 50 years ago with the proposition and experimental demonstrations that angiogenesis is instrumental for tumor growth and was, therefore, a promising therapeutic target. The biological knowledge and therapeutic insights forthcoming have been remarkable, punctuated by new concepts, many of which were not foreseen in the early decades. This article presents a perspective on tumor vascularization and its therapeutic targeting but does not portray a historical timeline. Rather, we highlight eight conceptual milestones, integrating initial discoveries and recent progress and posing open questions for the future.

Recent discoveries on the historical foundations of cancer risk assessment: Shedding light on the limits of LNT.

Within the past three years there has been a spate of historical discoveries by our research team on various different facets of the historical foundations of cancer risk assessment. This series of discoveries was stimulated by the creation of a 22-episode documentary of the historical foundations of cancer risk assessment by the US Health Physics Society and the need to provide documentation. This process yielded nearly two dozen distinct historical findings which have been published in numerous papers in the peer-reviewed literature. These discoveries are itemized and summarized in the present paper, along with the significance of each discovery within the historical context of ionizing radiation research and cancer risk assessment.

A historical and palaeopathological perspective on cancer.

Cancer is often wrongly considered to be a modern disease in many popular medical venues. Cancers have been known to humanity since ancient times. In fact, its antiquity can be identified through the application of palaeopathological methodologies. The present perspective demonstrates by means of a historical and palaeopathological analysis how oncological manifestations were present long before the emergence of anatomically modern humans and addresses the epidemiological transition from ancient times to the contemporary world. The final section of the article examines breast cancer and its identification in ancient human remains.

Bringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers.

Dogs are humanity's oldest friend, the first species we domesticated 20,000-40,000 years ago. In this unequaled collaboration, dogs have inadvertently but serendipitously been molded into a potent human cancer model. Unlike many common model species, dogs are raised in the same environment as humans and present with spontaneous tumors with human-like comorbidities, immunocompetency, and heterogeneity. In breast, bladder, blood, and several pediatric cancers, in-depth profiling of dog and human tumors has established the benefits of the dog model. In addition to this clinical and molecular similarity, veterinary studies indicate that domestic dogs have relatively high tumor incidence rates. As a result, there are a plethora of data for analysis, the statistical power of which is bolstered by substantial breed-specific variability. As such, dog tumors provide a unique opportunity to interrogate the molecular factors underpinning cancer and facilitate the modeling of new therapeutic targets. This review discusses the emerging field of comparative oncology, how it complements human and rodent cancer studies, and where challenges remain, given the rapid proliferation of genomic resources. Increasingly, it appears that human's best friend is becoming an irreplaceable component of oncology research.

Premios Nobel y cáncer / Nobel laureates and cancer

Los premios Nobel surgen en 1895 cuando Alfred Nobel firma su testamento dejando una gran parte de su riqueza a la creación de la Fundación Nobel y para el establecimiento de premios, a personas capaces de ayudar a mejorar la humanidad a través del conocimiento, la ciencia y el humanismo. Este premio se otorga en áreas, como la física, fisiología o medicina, química, literatura, paz y economía. Inició en 1901 y se mantiene hasta la actualidad, donde se han galardonado a 943 personas y 25 organizaciones. La historia y conocimientos conmemorados en los premios Nobel ha permitido un desarrollo íntegro en la comprensión, diagnóstico, terapia y progresos científicos en los diversos tipos de cáncer, sentando las bases y siendo la inspiración de miles de científicos a nivel mundial que trabajan arduamente en el área de la oncología. Estimaciones de la web GLOBOCAN indican que a nivel mundial se produjeron aproximadamente 19 millones de nuevos casos de cáncer y casi 10 millones de muertes por cáncer solo en el 2020. Este estudio tiene como objetivo revisar y reunir los principales descubrimientos científicos premiados con el Nobel en el área de la fisiología o medicina y química, que contribuyeron al conocimiento, diagnóstico y/o tratamiento oncológico desde 1901 a 2021.

The Nobel Prize originated in 1895 when Alfred Nobel signed his will, leaving a large part of his wealth to the creation of the Nobel Foundation and the establishment of this prize, with the vision that people could help improve humanity through knowledge, science, and humanism. The Nobel Prize has been awarded in areas such as physics, physiology or medicine, chemistry, literature, peace, and economics. 943 people and 25 organizations have been awarded since 1901 to this day. The history and knowledge commemorated in the Nobel Prize have allowed an integral development in the understanding, diagnosis, therapy, and scientific progress in different types of cancer, laying the foundations and being the inspiration for thousands of scientists worldwide who work hard in the area of oncology. GLOBOCAN estimates indicated that there were approximately 19 million new cancer cases globally and almost 10 million cancer deaths in 2020 alone; hence, this study reviews and brings together the main scientific discoveries awarded with the Nobel Prize in the area of physiology or medicine and chemistry, which contributed to the knowledge, diagnosis and/or treatment of cancer from 1901 to 2021.

[Nobel laureates and cancer]. / Premios Nobel y cáncer.

The Nobel Prize originated in 1895 when Alfred Nobel signed his will, leaving a large part of his wealth to the creation of the Nobel Foundation and the establishment of this prize, with the vision that people could help improve humanity through knowledge, science, and humanism. The Nobel Prize has been awarded in areas such as physics, physiology or medicine, chemistry, literature, peace, and economics. 943 people and 25 organizations have been awarded since 1901 to this day. The history and knowledge commemorated in the Nobel Prize have allowed an integral development in the understanding, diagnosis, therapy, and scientific progress in different types of cancer, laying the foundations and being the inspiration for thousands of scientists worldwide who work hard in the area of oncology. GLOBOCAN estimates indicated that there were approximately 19 million new cancer cases globally and almost 10 million cancer deaths in 2020 alone; hence, this study reviews and brings together the main scientific discoveries awarded with the Nobel Prize in the area of physiology or medicine and chemistry, which contributed to the knowledge, diagnosis and/or treatment of cancer from 1901 to 2021.

Population-based survival for cancer patients in Saudi Arabia for the years 2005-2009.

The Saudi Cancer Registry reported in 2007 the 5-year observed survival for the most common cancer sites for the years 1994-2004. In this report we looked at the cancer survival in the period 2005-2009 and evaluated the trend over the 15 years period from 1994 to 2009. Cases of the top 14 cancer sites reported by the population based Saudi Cancer Registry from 1 January 2005 to December 31, 2009, were submitted for survival analysis. The vital status of those patients was collected. Analysis of survival for the above period was compared with the prior reported 2 periods (1994-1999, 2000-2004). In addition, analysis was done according to age, sex, disease stage and the province. Data of 25,969 patients of the commonest cancer sites were submitted. Of those 14,146 patients (54%) had complete demographic data available and vital status was reported. Thyroid cancer had the highest 5- year observed survival of 94% (95% confidence interval (CI) 93-95%)), followed by Breast (72%, 95% CI 71-74%). In hematological malignancies, Hodgkin's Lymphoma had the highest 5-year survival of 86% (95% CI 84-88%). Survival rates has improved in most of the cancers sites for the studied periods except for lung, uterine and Hodgkin's lymphoma which plateaued. Our study confirms a steady improvement in the 5-year observed survival over time for the majority of cancers. Our survival data were comparable to western countries. This data should be used by policy makers to improve on cancer care in the kingdom.

Introducing new group leaders: Leanne Li.

Leanne Li tells us about the research in her recently established group at the Francis Crick Institute in London, her search for a multidisciplinary institute, and how her own varied background came together to study the emerging field of cancer neuroscience. She shares advice for applying, her experience of remote hiring, and how diversity, both academically and culturally, stimulates creativity.

Introducing new group leaders: Christina Towers.

Christina Towers discusses her search for a collaborative institute and why she chose the Salk, San Diego, to establish her lab studying autophagy in cancer. She shares her advice for applying, the importance of identifying what you want, tackling the perceived requirement for geographic mobility, and her hope to hire people who share her curiosity and love of asking questions.

The association of minerals intake in three meals with cancer and all-cause mortality: the U.S. National Health and Nutrition Examination Survey, 2003-2014.

BACKGROUND: Intake time of diet has recently been demonstrated to be associated with the internal clock and circadian pattern. However, whether and how the intake time of minerals would influence the natural course of cancer was largely unknown. METHODS: This study aimed to assess the association of mineral intake at different periods with cancer and all-cause mortality. A total of 27,455 participants aged 18-85 years old in the National Health and Nutrition Examination Survey were recruited. The main exposures were the mineral intakes in the morning, afternoon and evening, which were categorized into quintiles, respectively. The main outcomes were mortality of cancer and all causes. RESULTS: During the 178,182 person-years of follow-up, 2680 deaths, including 601 deaths due to cancer, were documented. After adjusting for potential confounders, compared to the participants who were in the lowest quintile(quintile-1) of mineral intakes at dinner, the participants in the highest quintile intake(quintile-5) of dietary potassium, calcium and magnesium had lower mortality risks of cancer (HRpotassium = 0.72, 95% CI:0.55-0.94, P for trend = 0.023; HRcalcium = 0.74, 95% CI:0.57-0.98, P for trend = 0.05; HRmagnesium = 0.75, 95% CI:0.56-0.99, P for trend = 0.037) and all-cause (HRpotassium = 0.83, 95% CI:0.73-0.94, P for trend = 0.012; HRcalcium = 0.87, 95% CI:0.76-0.99, P for trend = 0.025; HRmagnesium = 0.85, 95% CI:0.74-0.97, P for trend = 0.011; HRcopper = 0.80, 95%CI: 0.68-0.94, P for trend = 0.012). Further, equivalently replacing 10% of dietary potassium, calcium and magnesium consumed in the morning with those in the evening were associated with lower mortality risk of cancer (HRpotassium = 0.94, 95%CI:0.91-0.97; HRcalcium = 0.95, 95%CI:0.92-0.98; HRmagnesium = 0.95, 95%CI: 0.92-0.98). CONCLUSIONS: This study demonstrated that the optimal intake time of potassium, calcium and magnesium for reducing the risk of cancer and all-cause mortality was in the evening.

A Nobel-Winning Scientist: Aziz Sancar and the Impact of his Work on the Molecular Pathology of Neoplastic Diseases.

Aziz Sancar, Nobel Prize winning Turkish scientist, made several discoveries which had a major impact on molecular sciences, particularly disciplines that focus on carcinogenesis and cancer treatment, including molecular pathology. Cloning the photolyase gene, which was the initial step of his work on DNA repair mechanisms, discovery of the "Maxicell" method, explanation of the mechanism of nucleotide excision repair and transcription-coupled repair, discovery of "molecular matchmakers", and mapping human excision repair genes at single nucleotide resolution constitute his major research topics. Moreover, Sancar discovered the cryptochromes, the clock genes in humans, in 1998, and this discovery led to substantial progress in the understanding of the circadian clock and the introduction of the concept of "chrono-chemoterapy" for more effective therapy in cancer patients. This review focuses on Aziz Sancar's scientific studies and their reflections on molecular pathology of neoplastic diseases. While providing a new perspective for researchers working in the field of pathology and molecular pathology, this review is also an evidence of how basic sciences and clinical sciences complete each other.